Navigation Links
Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
Date:12/12/2007

diesse for many of their patients is first and foremost that they believe their patients are more satisfied with Radiesse than other dermal filler options. The published report of the comparative study of Radiesse against leading hyaluronic acid fillers demonstrates this difference in a well-controlled clinical study setting," commented Steven Basta, Chief Executive Officer of BioForm Medical. "We are grateful to the many investigators in the U.S. and European clinical studies, and to the leading physicians who routinely take time out of their practice to report on their growing positive experiences with Radiesse."

Radiesse vs. Juvederm and Perlane Clinical Trial

A 205-patient comparative study was conducted at five clinical sites in Europe to assess patient satisfaction and aesthetic improvement in treating nasolabial folds with Radiesse dermal filler as compared to three leading hyaluronic acid fillers, Perlane and two forms of Juvederm. The results of this prospective, multi-center, randomized study, led by Marion Moers-Carpi, MD, Hautok, Munich, Germany, demonstrated higher patient satisfaction, higher likelihood to return for additional treatment, and a greater likelihood to recommend treatment with Radiesse dermal filler, as compared to the three hyaluronic acid products tested: Juvederm 24 (not available in the U.S.), Juvederm 24HV (known as Juvederm Ultra in the U.S.) and Perlane. The study was designed to measure the results achieved by several products on a comparative basis after the completion of two treatments, at baseline and at four months in order to achieve optimal correction. The paper published in the Journal of Dermatologic Surgery reports on results achieved through a 12-month follow-up after the second treatment.

The results from the study demonstrated that at 12 months after the last injection, 90% of Radiesse treated patients rated their satisfaction as "satisfied" or "extremely satisfied" compared to 48% with Perlane (p<
'/>"/>

SOURCE BioForm Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
3. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
6. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
7. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
10. Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
11. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... entitled " Lovetraction Lines ." It's for women interested in improving their love ... desire. The course, which officially launched to the public early this morning, has ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association ... and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to ... will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality provider of ... announced that the Centers for Medicare and Medicaid (CMS) have awarded its agency the ... 24/7 Care At Home’s agency is one of three top Orange County agencies to ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Western ... success of the 2015 Special Olympics World Games, the largest sports and humanitarian event ... the 1984 Olympic Games. , The World Games, held July 25 through August 2, ...
Breaking Medicine News(10 mins):Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3
... oral cancer, which a dentist could perform by simply using ... set to be developed by researchers at the University of ... The international research team, involving scientists in Sheffield, has been ... to develop the test, which could provide an accurate diagnosis ...
... available in French . Inhibiting prostate cancer ... governs tumour growth A kinase is a type of ... proteins required for cell growth and maintenance, and researchers have ... developing prostate cancer. "It,s known as Mnk, and although it ...
... College of Nursing has been awarded a $753,817 grant ... Health Resources and Services Administration (HRSA), to prepare advanced ... high quality healthcare in rural and medically underserved urban ... to i-LEAD, Innovation in Leadership and Administration in Nursing ...
... Comprehensive Cancer Center and the departments of Chemistry ... uncovered a role for an essential cell protein ... "power plant" of the cell. The import ... for the replication, transcription and translation of the ...
... is twofold, as the patients not only suffer from ... called phantom pain. Unlike bodily wounds which will eventually ... a lifetime. "Phantom pain is very difficult to treat", ... "Mostly they prove to be highly therapy-resistant", the Professor ...
... , THURSDAY, Aug. 5 (HealthDay News) -- While maintaining ... of heart disease and diabetes, being overweight may actually ... researchers say. This new finding suggests that overweight ... open-angle glaucoma (POAG), one of the most common age-related ...
Cached Medicine News:Health News:New 'dentist' test to detect oral cancer will save lives 2Health News:New 'dentist' test to detect oral cancer will save lives 3Health News:Inhibiting prostate cancer without disturbing regular body processes 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 2Health News:College of Nursing awarded grant for nursing leadership in rural and underserved areas 3Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 2Health News:UCLA researchers discover protein that shuttles RNA into cell mitochondria 3Health News:Prosthesis with information at its fingertips 2Health News:Excess Weight May Protect Women From Type of Glaucoma 2Health News:Excess Weight May Protect Women From Type of Glaucoma 3
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: